Cardiometabolic research stands at the intersection of some of the most complex and prevalent health challenges of our time. From the rising tide of obesity and metabolic-associated steatohepatitis (MASH) to the persistent burden of Type 2 Diabetes Mellitus (T2DM) and hypertension, trials in this space require more than just patient volume. They demand a sophisticated understanding of multi-system pathologies and a rigorous commitment to data integrity. DelRicht Research has established itself as a premier partner for sponsors and CROs, offering a physician-led network that transforms these clinical complexities into predictable, high-performing outcomes.

A Legacy of Proven Experience and Regulatory Success

Over the past six years, our network has successfully navigated 14 cardiometabolic trials, enrolling over 450 participants. Our track record is defined by a consistent ability to outpace industry benchmarks; in fact, 96% of our network trials meet or exceed enrollment goals. This performance is anchored by our 17 specialized investigators who bring a collective 320+ years of principal investigator experience to every protocol.

DelRicht’s impact on the cardiometabolic landscape is best demonstrated by our role in advancing therapeutics toward market readiness. Our network played a role in providing quality clinical data that supported the FDA approval of Farxiga® (dapagliflozin) for AstraZeneca, a landmark therapy in the cardiorenal and metabolic space.

Nationwide Infrastructure and Diverse Patient Access

The DelRicht model is built on 17 experienced sites nationwide, deeply embedded within high-volume, community-based physician clinics. This “embedded” approach provides a dual advantage for sponsors:

– Immediate Access to Real-World Patients: We do not rely on traditional advertising alone. Our investigators have direct access to established patient bases with chronic and interconnected conditions like T2DM, hypertension, and obesity.

– Representative Diversity: We understand that cardiometabolic diseases disproportionately affect underserved populations. Our sites maintain an average 45%+ patient diversity, ensuring that trial data is robust, inclusive, and reflective of the real-world populations who will ultimately use the therapy.

Each site is equipped with a full-service infrastructure, including secure IP storage, access to local laboratories, and access to dieticians, an essential component for weight management and metabolic syndrome studies.

Operational Precision and Rapid Start-Up

In a competitive landscape where First Patient In is a critical milestone, DelRicht delivers industry-leading speed. Our operational model is designed to minimize the gap between site award and trial activation.

Our recent performance metrics highlight this efficiency through rapid activation to screen and award to activation. Across six recent cardiometabolic studies, our sites achieved an average of 2.1 days from activation to first patient first visit, with several sites achieving same-day screening.

Expertise Across the Cardiometabolic Spectrum

Our investigators are not generalists; they are specialists in the nuances of cardiometabolic health. DelRicht has successfully executed protocols across a broad range of indications, including obesity and weight management, hypertension, diabetic peripheral neuropathy (DNP), T2DM, and MASH. These indications each present their own trial challenges, like successful enrollment for qualified and motivated patients, navigating complex titration protocols, blood pressure monitoring, managing sensitive endpoints, and strict adherence to medication and diary compliance. No matter the protocol intricacy, our site teams are equipped to guide patients through studies with precision.

Patient-Centered Retention and Compliance

Cardiometabolic trials often require long-term follow-up and strict adherence to lifestyle or dosing regimens. Retention can be a challenge in these chronic populations, but DelRicht mitigates this risk through integrated patient support. Our full-time site staff provides extensive education and real-time consent support, which has resulted in retention rates as high as 93.3% across 8 recent cardiometabolic studies.

Your Partner for Clinical Success

Whether you are navigating a Phase II dose-finding study or a large-scale Phase III cardiovascular outcomes trial (CVOT), DelRicht Research provides the predictability, speed, and quality data required for success. We invite sponsors and CROs to leverage our proven infrastructure and therapeutic depth to move your next cardiometabolic asset forward. Let’s talk about your next trial. DelRicht Research is ready to deliver.